Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001415889-13-002325
Filing Date
2013-11-14
Accepted
2013-11-14 16:56:13
Documents
11
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 fpmi10qsept302013.htm 10-Q 670908
2 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARB ex31-1.htm EX-31.1 17733
3 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARB ex31-2.htm EX-31.2 17699
4 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ex32-1.htm EX-32.1 5437
5 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ex32-2.htm EX-32.2 5596
  Complete submission text file 0001415889-13-002325.txt   3831241

Data Files

Seq Description Document Type Size
6 fpmi-20130930.xml EX-101.INS 397670
7 fpmi-20130930.xsd EX-101.SCH 44615
8 fpmi-20130930_pre.xml EX-101.PRE 208978
9 fpmi-20130930_lab.xml EX-101.LAB 286799
10 fpmi-20130930_def.xml EX-101.DEF 87950
11 fpmi-20130930_cal.xml EX-101.CAL 41815
Mailing Address 8 HILLSIDE AVENUE SUITE 207 MONTCLAIR NJ 07042
Business Address 8 HILLSIDE AVENUE SUITE 207 MONTCLAIR NJ 07042 973-744-1565
FLUOROPHARMA MEDICAL, INC. (Filer) CIK: 0001402785 (see all company filings)

EIN.: 208325616 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 333-147193 | Film No.: 131221085
SIC: 2835 In Vitro & In Vivo Diagnostic Substances